ポスト

さすがそーせい様。

メニューを開く
Nxera Pharma@NxeraPharma

NBI-1117568, our partnered M4 receptor agonist being advanced in Phase 2 clinical trials by @neurocrine, has successfully completed a long-term preclinical toxicity program triggering a $15 million milestone payment to Nxera from Neurocrine. Read more: bit.ly/49FQQzF

田舎者(天草地方出身者)@imoame0801

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ